Results 1 to 10 of about 162,494 (358)

Machine learning models to predict the warfarin discharge dosage using clinical information of inpatients from South Korea

Scientific Reports, 2023
As warfarin has a narrow therapeutic window and obvious response variability among individuals, it is difficult to rapidly determine personalized warfarin dosage.
Heejung Choi, Hee Jun Kang, Imjin Ahn, Hansle Gwon, Yunha Kim, Hyeram Seo, Ha Na Cho, JiYe Han, Minkyoung Kim, Gaeun Kee, Seohyun Park, Osung Kwon, Jae-Hyung Roh, Ah-Ram Kim, Ju Hyeon Kim, Tae Joon Jun, Young-Hak Kim   +16 more
doaj   +1 more source

Structural Changes of Sodium Warfarin in Tablets Affecting the Dissolution Profiles and Potential Safety of Generic Substitution

Pharmaceutics, 2021
At present, the risk of generic substitutions in warfarin tablets is still being discussed. The aim of this study was to assess whether API interactions with commonly used excipients may affect the safety of generic replacement of warfarin sodium tablets.
Jan Muselík, Martina Urbanova, Eva Bartoníčková, Jakub Palovčík, David Vetchý, Jiří Czernek, Larisa Janisova, Nadiia Velychkivska, Aleš Franc, Jiří Brus   +9 more
doaj   +1 more source

Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]

, 2019
© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ, Farag, Mohamed, Gorog, Diana, Gue, Ying X., Lip, Gregory Y H, Spinthakis, Nikolaos, Srinivasan, Manivannan, Wellsted, David   +7 more
core   +3 more sources

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

An Atypical Case of Warfarin-Induced Skin Necrosis

Clinical Practice and Cases in Emergency Medicine, 2017
Skin necrosis is a relatively rare, potentially fatal side effect of warfarin. It is most commonly reported within 10 days of initiation of therapy in warfarin-naïve patients.
Lindsay R. Sklar, Anne Messman
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
A. John Camm, AC Skanes, AG Turpie, AJ Camm, AK Kakkar, AT Cohen, B Laulicht, BF Gage, BI Eriksson, BI Eriksson, BI Eriksson, BI Eriksson, BS Stambler, C Kearon, CB Granger, CT Ruff, DE Salazar, G Agnelli, G Agnelli, G Lu, G Raskob, G Raskob, H Masumoto, H Zahir, Henri Bounameaux, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Mendell, J Stampfuss, JH Alexander, JI Weitz, JL Mega, K Ogata, KL Furie, LT Grip, M Crowther, M Hori, M Pirmohamed, MR Lassen, MR Lassen, MR Lassen, MR Lassen, MR Patel, MS Bathala, MU Zafar, N Chung, N Matsushima, R Caterina De, R Caterina De, RP Giugliano, S Kaatz, S Schulman, S Schulman, S Schulman, SE Kimmel, SJ Connolly, SJ Connolly, SJ Connolly, SZ Goldhaber, T Fuji, T Fuji, T Fukuda, T Hulle van der, T Mikkaichi, T Wilke, T Yamashita, TI Verhoef, W Mueck, Y Falck-Ytter, Y Kuroda   +72 more
core   +1 more source

The Active Metabolite of Warfarin (3'-Hydroxywarfarin) and Correlation with INR, Warfarin and Drug Weekly Dosage in Patients under Oral Anticoagulant Therapy: A Pharmacogenetics Study. [PDF]

PLoS ONE, 2016
Warfarin oral anticoagulant therapy (OAT) requires regular and frequent drug adjustment monitored by INR. Interindividual variability, drug and diet interferences, and genetics (VKORC1 and CYP2C9) make the maintenance/reaching of stable INR a not so easy
Donato Gemmati, Francesco Burini, Anna Talarico, Matteo Fabbri, Cesare Bertocco, Marco Vigliano, Stefano Moratelli, Antonio Cuneo, Maria Luisa Serino, Francesco Maria Avato, Veronica Tisato, Rosa Maria Gaudio   +11 more
doaj   +1 more source

Enzyme polymorphism in warfarin dose management after pediatric cardiac surgery

Research in Cardiovascular Medicine, 2015
Background: Warfarin is an anticoagulant and is widely used for the prevention of thromboembolic events. Genetic variants of the enzymes that metabolize warfarin, i.e.
Avisa Tabib, Babak Najibi, Mohammad Dalili, Ramin Baghaei, Behzad Poopak   +4 more
doaj   +1 more source

Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]

, 2016
BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core   +2 more sources

Standardized warfarin monitoring decreases adverse drug reactions

BMC Family Practice, 2019
Background While warfarin is the most commonly prescribed medication to prevent thromboembolic disorders, the risk of adverse drug reactions (ADR) poses a serious concern.
Lisa B. E. Shields, Paula Fowler, Diane M. Siemens, Douglas J. Lorenz, Kenneth C. Wilson, Steven T. Hester, Joshua T. Honaker   +6 more
doaj   +1 more source